Crystalline phases of 5,6-dichloro-2-(isopropylamino)-(1 β-L-ribofuranosyl)-1H-benzimidazole
AssigneeTakeda Pharmaceutical Company Limited
InventorsGerard Coquerel, Guillaume Levilain, Marie-Noelle Petit, Servane Coste-Leconte
Life of this patent
Estimating the term…
Abstract
The invention relates to novel crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.
Claims13
A crystalline form of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, wherein the crystalline form is a hydrochloride monohydrate salt, and wherein the crystalline form has unit cell parameters a=22.25 Å, b=22.25 Å, c=8.016 Å, and P42212 space group (recorded at 293 K).
A crystalline form of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, wherein the crystalline form is a hydrochloride monohydrate salt, and wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising peaks at 5.619±0.1° and 7.996±0.1°2-theta.
Dependencies are inferred from the claim text.